Holly Kordasiewicz

Ionis Pharmaceuticals (United States) — United States

Neuroscience · Life Sciences

38h-index7.7kcitations109works2.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genetic Neurodegenerative Diseases(39), Mitochondrial Function and Pathology(20), Neurogenetic and Muscular Disorders Research(16), RNA Research and Splicing(14), Muscle Physiology and Disorders(12)

Publications109 total

Transient acute neuronal activation response caused by high concentrations of oligonucleotides in the cerebral spinal fluid
Nucleic Acids Research·2026Open Access
Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA model
Molecular Therapy — Nucleic Acids·2025Open Access
Acute neuronal inhibition response caused by phosphorothioate antisense oligonucleotides following local delivery to the central nervous system
Nucleic Acids Research·2025· 1 citedOpen Access
Suppression of Huntington’s Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding
Nature Communications·2025Open Access
Author response: An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome
2025Open Access
Analgesic actions of Intrathecal NaV 1.7 antisense in rats: loss of antagonist channel binding, message depletion, and neuraxial distribution of oligonucleotide
2025Open Access
An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome
eLife·2025· 1 citedOpen Access
Altered huntingtin−chromatin interactions predict transcriptional and epigenetic changes in Huntington's disease
Disease Models & Mechanisms·2025· 4 citedOpen Access
ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses
Molecular Neurodegeneration·2025· 4 citedOpen Access
An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome
2025· 1 citedOpen Access
Author response: An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome
2025Open Access
Atrophin-1 Antisense Oligonucleotide Provides Robust Protection from Pathology in a Fully Humanized DRPLA Model
2025Open Access
Reversable Acute Sedation Response of Phosphorothioate Antisense Oligonucleotides Following Local Delivery to the Central Nervous System
2025· 4 citedOpen Access
Transient Acute Neuronal Activation Response Caused by High Concentrations of Oligonucleotides in the Cerebral Spinal Fluid
2025· 3 citedOpen Access
Antisense oligonucleotide–mediated MSH3 suppression reduces somatic CAG repeat expansion in Huntington’s disease iPSC–derived striatal neurons
Science Translational Medicine·2025· 20 citedOpen Access
Antisense‐mediated APP suppression as potential therapeutic for Down Syndrome Alzheimer’s Disease
Alzheimer s & Dementia·2024Open Access
An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome
2024Open Access
An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome
eLife·2024· 3 citedOpen Access
Suppression of Huntington’s Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding
2024· 6 citedOpen Access
ASO-mediated knockdown of GPNMB in mutant- <i>GRN</i> and <i>Grn</i> -deficient peripheral myeloid cells disrupts lysosomal function and immune responses
2024Open Access
page 1 of 6Next →

Frequent Co-authors

Eric E. Swayze(22), C. Frank Bennett(13), Hien Zhao(13), Curt Mazur(8), Don W. Cleveland(5), Timothy M. Miller(5), Bethany Fitzsimmons(5), Roger Lane(5), Michael E. Østergaard(5), Amber L. Southwell(5), Niels H. Skotte(5), Crystal N. Doty(5), Michael R. Hayden(5), Punit P. Seth(5), Jeffrey B. Carroll(5), Eric Vallabh Minikel(5), Sonia M. Vallabh(5), Gene Hung(4), Daniel A. Norris(4), Danielle Graham(4)